Marta Sbaraglia Selected Research

Marta Sbaraglia Research Topics

Disease

20	Neoplasms (Cancer) 01/2024 - 01/2014
12	Sarcoma (Soft Tissue Sarcoma) 03/2024 - 10/2016
3	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2023 - 02/2021
3	Ewing Sarcoma (Sarcoma, Ewing) 01/2021 - 10/2016
3	Perivascular Epithelioid Cell Neoplasms 10/2020 - 01/2019
2	Renal Cell Carcinoma (Grawitz Tumor) 04/2024 - 04/2023
2	Chondrosarcoma 01/2024 - 01/2019
2	Disease Progression 11/2023 - 01/2021
2	Squamous Cell Carcinoma of Head and Neck 06/2023 - 03/2021
2	Osteosarcoma (Osteogenic Sarcoma) 09/2022 - 09/2021
2	Margins of Excision 03/2022 - 12/2016
2	Leiomyosarcoma 01/2022 - 08/2015
2	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2021
2	Stomach Neoplasms (Stomach Cancer) 10/2021 - 10/2021
2	Chondroblastoma 09/2021 - 06/2021
1	Aggressive Fibromatosis (Desmoid) 11/2023
1	Pain (Aches) 11/2023
1	Smooth Muscle Tumor 11/2023
1	Lipoma (Lipomata) 03/2023
1	Kidney Calculi (Kidney Stone) 03/2023
1	Merkel Cell Carcinoma 12/2022
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2022
1	Carcinoma (Carcinomatosis) 07/2022
1	Synovial Sarcoma (Synovioma) 03/2022
1	Papillary Thyroid Cancer 01/2022
1	COVID-19 01/2022
1	Heart Diseases (Heart Disease) 01/2022
1	Infections 01/2022
1	Papillomavirus Infections 01/2022
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2022
1	Adenocarcinoma 10/2021
1	Gastritis 10/2021
1	Osteoblastoma 09/2021
1	Melanoma (Melanoma, Malignant) 05/2021
1	Carcinogenesis 01/2021
1	Thyroid Neoplasms (Thyroid Cancer) 01/2021
1	Menstruation Disturbances 01/2021
1	Epithelioid Hemangioendothelioma 01/2021
1	Ductal Carcinoma 01/2021
1	Silicosis 04/2020
1	Pneumoconiosis 04/2020
1	Necrosis 04/2020

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 04/2023 - 01/2019
3	Inosine Triphosphate (ITP)IBA 01/2023 - 02/2021
3	RNA (Ribonucleic Acid)IBA 12/2022 - 01/2020
3	TrabectedinIBA 01/2022 - 10/2016
3	MTOR InhibitorsIBA 10/2020 - 01/2019
2	NivolumabIBA 04/2024 - 04/2023
2	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 03/2021
2	Indicators and Reagents (Reagents)IBA 06/2023 - 05/2021
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2022 - 01/2017
2	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2021
2	CateninsIBA 09/2021 - 11/2020
2	Sirolimus (Rapamycin)FDA Link 01/2021 - 10/2020
2	pazopanib FDA Link 01/2020 - 01/2018
2	Gemcitabine FDA Link 01/2020 - 01/2018
2	AnthracyclinesIBA 01/2020 - 01/2018
1	Genetic Markers (Genetic Marker)IBA 01/2024
1	ParaffinIBA 01/2024
1	Codon (Codons)IBA 01/2024
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2024
1	Progesterone Receptors (Progesterone Receptor)IBA 11/2023
1	Estrogens (Estrogen)FDA Link 11/2023
1	Angiogenesis InhibitorsIBA 06/2023
1	Capsules (Microcapsules)IBA 03/2023
1	A 19IBA 03/2023
1	Nerve Growth Factor Receptors (Neurotrophin Receptors)IBA 12/2022
1	Histones (Histone)IBA 09/2022
1	LigandsIBA 07/2022
1	AntibodiesIBA 03/2022
1	Surface-Active Agents (Surfactants)IBA 01/2022
1	olaparibIBA 01/2022
1	Imatinib Mesylate (Gleevec)FDA Link 01/2022
1	Protein CIBA 01/2022
1	Thrombopoietin ReceptorsIBA 01/2022
1	Protein Isoforms (Isoforms)IBA 10/2021
1	Tight Junction ProteinsIBA 10/2021
1	beta CateninIBA 09/2021
1	Mucin-4IBA 06/2021
1	Immune Checkpoint InhibitorsIBA 05/2021
1	Granzymes (Granzyme)IBA 05/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	Transcriptional Coactivator with PDZ-Binding Motif ProteinsIBA 01/2021
1	AntigensIBA 11/2020
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 10/2020
1	exemestane (Aromasin)FDA Link 10/2020
1	Estrogen Receptor Modulators (Antiestrogen)IBA 10/2020
1	QuartzIBA 04/2020
1	A-factor (Streptomyces)IBA 04/2020

Therapy/Procedure

10	Therapeutics 11/2023 - 01/2019
7	Drug Therapy (Chemotherapy) 03/2024 - 10/2016
3	Radiotherapy 11/2023 - 01/2022
2	Immunotherapy 04/2024 - 04/2023
1	Splenectomy 01/2023
1	Operative Surgical Procedures 01/2022
1	Secondary Prevention 10/2021
1	Thymectomy 08/2021
1	Adjuvant Radiotherapy 01/2021
1	Neoadjuvant Therapy 01/2021